Early Prediction of Radiotherapeutic Efficacy in a Mouse Model of Non-Small Cell Lung Carcinoma Using 18F-FLT and 18F-FDG PET/CT.

This study investigated the usefulness of [¹⁸F]-3'-deoxy-3'-fluorothymidine (¹⁸F-FLT) and [¹⁸F]-fluoro-2-deoxy-D-glucose (¹⁸F-FDG) positron emission tomography (PET)/computed tomography (CT) imaging for predicting the therapeutic efficacy of non-small cell lung cancer (NSCLC) irradiation at an early stage after radiation treatment. Mice were xenografted with the human lung adenocarcinoma line A549 or large cell lung cancer line FT821. Tumour uptake of ¹⁸F-FLT and ¹⁸F-FDG was imaged using PET/CT before and 1 week after irradiation. In A549 tumours, ¹⁸F-FLT uptake was significantly decreased, and ¹⁸F-FDG uptake was unchanged post-irradiation compared with pre-irradiation. In FT821 tumours, uptake of both ¹⁸F-FLT and ¹⁸F-FDG uptake was substantially decreased post-irradiation compared with pre-irradiation. In both xenografts, tumour volumes in the irradiated groups were significantly decreased compared with those in the control group. ¹⁸F-FLT is expected to contribute to individual NSCLC therapy because it accurately evaluates the decrease in tumour activity that cannot be captured by ¹⁸F-FDG. ¹⁸F-FDG may be useful for evaluating surviving cells without being affected by the inflammatory reaction at an extremely early stage, approximately 1 week after irradiation. Combined use of ¹⁸F-FLT and ¹⁸F-FDG PET/CT imaging may increase the accurate prediction of radiotherapy efficacy, which may lead to improved patient outcomes and minimally invasive personalised therapy. [ABSTRACT FROM AUTHOR]